OncoTherapy Science, Inc.

DB:30O Stock Report

Market Cap: €38.2m

OncoTherapy Science Past Earnings Performance

Past criteria checks 0/6

OncoTherapy Science has been growing earnings at an average annual rate of 14.9%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 20.5% per year.

Key information

14.9%

Earnings growth rate

21.3%

EPS growth rate

Biotechs Industry Growth-14.6%
Revenue growth rate20.5%
Return on equity-112.4%
Net Margin-234.4%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How OncoTherapy Science makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

DB:30O Revenue, expenses and earnings (JPY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24479-1,1232650
30 Jun 24562-1,1902600
31 Mar 24610-1,2882610
31 Dec 23901-1,1922550
30 Sep 23976-1,2152700
30 Jun 23897-1,2412770
31 Mar 231,134-1,1182870
31 Dec 221,517-1,3452930
30 Sep 221,427-1,9552890
30 Jun 221,445-2,3142940
31 Mar 221,153-2,5712940
31 Dec 21507-2,5183910
30 Sep 21472-2,0343580
30 Jun 21384-1,7773270
31 Mar 21332-1,5612810
31 Dec 20315-1,6451820
30 Sep 20312-1,7382050
30 Jun 20302-1,9112400
31 Mar 20316-2,2382710
31 Dec 19194-2,8153810
30 Sep 19360-2,6483550
30 Jun 19322-2,9323340
31 Mar 19280-2,9342960
31 Dec 18255-2,5992680
30 Sep 1834-3,0262660
30 Jun 1824-2,9302490
31 Mar 18211-2,8512510
31 Dec 17255-2,9491920
30 Sep 17453-2,8722140
30 Jun 17486-2,8062340
31 Mar 17286-3,0022620
31 Dec 16290-2,8642780
30 Sep 1692-2,9512850
30 Jun 1660-3,0122950
31 Mar 16266-2,7882960
31 Dec 15581-2,4643190
30 Sep 15626-1,9213020
30 Jun 15671-1,7062960
31 Mar 15769-1,3342820
31 Dec 14651-1,7692250
30 Sep 141,035-2,4092290
30 Jun 141,110-2,7932500
31 Mar 141,017-3,6762350
31 Dec 132,303-2,4252930

Quality Earnings: 30O is currently unprofitable.

Growing Profit Margin: 30O is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 30O is unprofitable, but has reduced losses over the past 5 years at a rate of 14.9% per year.

Accelerating Growth: Unable to compare 30O's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 30O is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).

Return on Equity

High ROE: 30O has a negative Return on Equity (-112.41%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 13:48
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

OncoTherapy Science, Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kiyokazu YamazakiIchiyoshi Research Institute Inc.
Toshiyuki IwataMizuho Securities Co., Ltd.